CHC announced on June 18 that its Shin-ho Biotech Irradiation Plant has officially commenced operations. In addition to securing sterilization orders from the agricultural and food industries, the facility has begun testing services for the electronics and aerospace sectors. The next phase will focus on medical device industry clients, collaborating with Taiwanese companies to connect with international markets.
A grand opening ceremony for the irradiation plant was held on June 18 at the Tongluo Park in Hsinchu Science Park. Hsinchu Science Park Bureau Director Yung-Chuang Wang attended the event and highlighted in his speech that the Tongluo Science Park, situated between Hsinchu and Central Taiwan Science Parks, hosts industries including advanced semiconductor testing and materials, intelligent machinery, automotive electronics, and biotechnology. The opening of CHC’s SynCore Biotechnology Irradiation Plant will enhance the technological corridor in western Taiwan, linking the Hsinchu and Central Taiwan Science Parks and fostering mutual benefits for upstream and downstream companies.
CHC revealed that this state-of-the-art, high-energy irradiation plant, built with a NT$1 billion investment, is Asia’s first of its kind. It offers sustainable irradiation technology that leaves no radiation residue, contains no chemical carcinogens, is not limited by product packaging types, and has a wide range of applications.
CHC noted the recent food safety crises, with many products being pulled from shelves due to toxic carcinogenic ethylene oxide (EO) residues. The company’s selection of the Belgian IBA Rhodotron TT300 Duo dual-source accelerator, a leading global irradiation system, provides electron beam (E-beam) and photon (X-ray) irradiation. For the agricultural and food industries, irradiation can achieve pest control, sterilization, and preservation, replacing traditional EO sterilization and offering a safer sterilization option to enhance food safety.
Beyond applications in everyday consumer industries, CHC’s irradiation technology will also serve the domestic biotech and medical device sectors. With the passage of the "Regenerative Medicine Act," the demand for sterile medical supplies is expected to surge, heightening the need for efficient sterilization. Additionally, this irradiation system can modify semiconductor wafers or advanced composite materials to improve silicon wafer current switching efficiency and assist in the testing and application of aerospace industrial composites.
CHC emphasized its nearly 50-year presence in the Taiwanese medical market, positioning itself as the leader in medical technology services. The company continues to push boundaries, diversifying its business portfolio starting from its medical core. The initiation of the irradiation business is expected to gradually contribute to revenue and positively impact overall profitability.
Resource (mandarin):
